Search results for: “diet “
-
Symposium highlights supplements, menopause, and other trending topics in nutrition
Nutrition experts, including Kevin Klatt, PhD, RD, and Hillary Wright, MEd, RDN, LDN, analyzed several diet-related considerations that could have downstream implications for an individual’s diabetes management.
-
Outstanding Scientific Achievement Award lecturer highlights evolution of unimolecular therapies
Timo D. Müller, PhD, shared his insights on hormonal control of metabolism by glucose-dependent insulinotropic polypeptide (GIP) and next-generation incretin-based polyagonists during a session recognizing his contributions to diabetes and metabolic research.
-
Outstanding Educator in Diabetes Award recipient: Value the stories behind the numbers
In her award lecture, Diana Isaacs, PharmD, BCACP, CDCES, BC-ADM, FADCES, FCCP, advocated embracing new tools and technology while keeping the people living with diabetes central to new approaches to care.
-
Expert panel addresses GLP-1 RAs’ factors, features, and future
Amid increasing attention for GLP-1 RAs, a panel of experts summarized a broad spectrum of topics related to these medications, including emerging pharmacological options, muscle physiology, obesity treatment for osteoarthritis, and nutritional counseling.
-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
REIMAGINE trials demonstrate efficacy of combination therapy for treating type 2 diabetes
Donna Ryan, MD, and other panelists reported on new data from phase 3 trials evaluating the combination of cagrilintide, which mimics amylin, and semaglutide, a glucagon-like peptide-1 receptor agonist, in adults.
-
Triple-hormone therapy demonstrates efficacy for type 2 diabetes and obesity
Activation of the glucagon receptor with retatrutide is being investigated in a large phase 3 program that includes 14 trials and more than 22,000 participants. Researchers, including Ania Jastreboff, MD, PhD, shared data from two of the trials, TRANSCEND-T2D-1 and TRIUMPH-1.
-
Joint ADA/IDF symposium to address malnutrition-related diabetes diagnosis, treatment, and research needs
Peter E. H. Schwarz, MD, PhD, MBA, and other leading experts from across the globe will discuss the latest information on the prevention, diagnosis, and treatment of what an international working group has designated as type 5 or malnutrition-related diabetes.
-
Session to address the economic and health value of obesity treatment
Panelists, including Tim Dall, MS, will help make business and social cases for investing in evidence-based treatment for obesity, such as lower healthcare costs, improved quality of life, and reduced mortality.
-
2026 Scientific Sessions opens four days of discovery
Jazz medleys, greetings from the American Diabetes Association® chief executive officer, an address on the future of diabetes research from a senior advisor at the National Institutes of Health, and highlights of cutting-edge science from ADA Pathway scientists marked the opening of the 2026 Scientific Sessions in New Orleans.